Overview

Allergic Rhinitis is a collection of symptoms, mostly in the nose and eyes, which occur as a result of the inhalation of an allergen, such as dust or pollen. Allergic Rhinitis is among the top five chronic medical conditions, estimated to affect between 10% to 30% of adults, and 40% of children. In each of the last three decades, there has been a 100% increase in the prevalence of Allergic Rhinitis in developed countries. In 2008, over US$1.7 billion in products to treat nasal allergies were sold in the United States.

TBS-6 – Allergic Rhinitis

Trimel’s product candidate (TBS-6) is under development to provide patients suffering from seasonal and perennial Allergic Rhinitis with leading nasally delivered corticosteroids. Current treatments result in side effects due to the delivery of the active ingredient by a nasal spray pump. Use of the TriVair™ to deliver TBS-6 may provide a superior outcome to the patient by achieving targeted delivery of the medication, by causing the back of the throat to close during its delivery of the medication.